Aarti Pharmalabs Submits BRSR Report for FY 2025-26

Aarti Pharmalabs Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as per SEBI Listing Regulations. The report details the company's corporate identity, registered and corporate office addresses, financial year, and stock exchange listings. It outlines the business activities, primarily focused on manufacturing Pharmaceuticals and Nutraceuticals, contributing 100% to turnover, with specific product segments including APIs, Pharmaceutical Intermediates, New Chemical Entities, and Xanthine Derivatives. The company operates across 15 national locations and serves 25 states and 51 countries, with exports accounting for approximately 55.93% of its total turnover. The BRSR also highlights the company's proactive approach to obtaining Type 2 Moderate Assurance for its Sustainability Report and BRSR Core indicators.